Skip to Main Content

Bluebird Bio (BLUE) is surprising investors Friday with some unexpectedly good news out of Europe.

A marketing application covering the Cambridge, Mass., biotech’s gene therapy for beta thalassemia was accepted for review by European regulators, Bluebird announced.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.